Ingenia Completes Public Offering Subscription...KOSDAQ Listing Set for the 18th
Competition Ratio Reaches 3.09 to 1
Ingenia Therapeutics, a biotech company developing antibody drugs for vascular diseases, announced on August 3 that it has completed its public offering subscription for general investors, which took place over two days starting July 30.
In this subscription, Ingenia achieved a competition ratio of 3.09 to 1. After collecting the subscription payments the following day, the company is scheduled to list on the KOSDAQ market on August 18.
The majority of the funds raised through the public offering will be used for research and development activities, such as accelerating clinical trials and expanding its pipeline. Ingenia aims to secure efficacy data for its chronic kidney disease (CKD) treatment candidate "IGT-303," which is currently in global Phase 2a clinical trials in Australia, New Zealand, and Korea, and to achieve global out-licensing by 2027.
The company also intends to accelerate the development of follow-up pipeline candidates including "IGT-302," a glaucoma treatment being collaboratively researched with Merck (MSD) in the United States; a solid tumor therapy (IGT-532); and a pulmonary arterial hypertension treatment (IGT-627).
Earlier, Ingenia successfully out-licensed its retinal disease treatment candidate "IGT-427" at the preclinical stage in a deal valued at over 1 trillion won.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Han Sangyeol, CEO of Ingenia, stated, “We will use this listing as a springboard to enhance our position in the global market by leveraging the value of our independently-developed microvascular normalization platform technology. In addition to delivering tangible results, we are fully committed to increasing shareholder value based on responsible management and transparent communication.”
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.